Health Economics›Thyroid cancer›Locally advanced or metastatic all lines of therapy

Locally advanced or metastatic all lines of therapy

Thyroid cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	~10.7 mo	—	~12	~R 633 492 PFS proxy · indirect	6
Vemurafenib monotherapy Variant #01	BRAF	R 13 464	28d	~7.2 mo	~15.5 mo	~8	~R 107 711 PFS proxy · indirect	4

2 of 2 regimens shown